This observation aligns with the known expression of nectin-4, the target of enfortumab vedotin, in epidermal keratinocytes and skin appendages.43 In the pivotal EV-302 trial, additional notable AEs included ocular disorders (21.0% vs 2.8% with chemotherapy) and hyperglycemia (13.0% vs 0.7% with chemotherapy).11 While these AEs were not consistently reported across all studies in the present meta-analysis, their observation in the large phase 3 trial warrants examination in future studies. The gene discussed is NECTIN4; the disease is Hyperglycemia.